• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Peter Paul Yu: How Next-Generation Sequencing Is Changing Cancer Care

Video

Next-generation sequencings tests are just starting to change the landscape for cancer patients, explained Peter Paul Yu, MD, FASCO, FACP, physician-in-chief, Hartford HealthCare Cancer Center.

Next-generation sequencings tests are just starting to change the landscape for cancer patients, explained Peter Paul Yu, MD, FASCO, FACP, physician-in-chief, Hartford HealthCare Cancer Center.

Transcript

How is next-generation sequencing changing the landscape for cancer care?

Next-generation sequencings tests are just starting to change the landscape for cancer patients. We’ve had quite a bit of FDA and CMS regulation just in the first half of this year, which have begun to lay down the road map for how the FDA will look at laboratory diagnostic tests based on genomics and how they will go about ascertaining the quality of that test and how CMS is starting to think about how they will decide when they will pay for these tests. So, the fact that we have the 2 major regulatory agencies in the United States starting to set policy is a big step forward.

However, the payment policy issued by the National Coverage Decision by CMS a couple of months ago is extremely narrow. It essentially, as I interpret it, limits it to when there is a specific genomic biomarker match to a specific drug that’s been FDA approved. In that circumstance, combined with a patient with advanced cancer, there will be payment for it. But, it’s still a very, very limited role.

The alternative is that we rely on traditional biomarker testing, which is either a series of sequential tests that consume a lot of sample, and very often you may run out of sample before you’ve done all your testing, or some limited panel, which is increasingly being look at as both an inefficient and expensive way of doing genomic testing.

So, I think that it’s good news that the FDA and CMS are recognizing that requiring a specific companion diagnostic test for every single drug that is precision medicine-based is no longer the way to go. But, we’re not quite there yet.

Related Videos
Will Shapiro
Shawn Kwatra, MD, dermatologist, John Hopkins University
Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients with Plaque Psoriasis
dr krystyn van vliet
Martin Dahl, PhD, senior vice president, AnaptysBio
Jeff Stark, MD, vice president, head of medical immunology, UCB.
Jonathan Silverberg, MD, PhD, MPH, FAAD, professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences
Monica Li, MD, University of British Columbia
Robert Sidbury, MD, MPH, FAAD, professor of pediatrics, division head of dermatology, Seattle Children's Hospital, University of Washington School of Medicine
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.